Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double blind placebo controlled dose-ranging study of RPL554 in moderate to severe COPD
2016-005205-40Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Started May 2017; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-005205-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005205-40.